OraSure Technologies | OSUR - Cash And Equivalent


OraSure Technologies reported $176.96M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
AngioDynamics USD 41.64M 14.26M Sep/2025
Becton, Dickinson and Co. USD 813M 73M Mar/2026
Bio Techne USD 209.82M 36.94M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Cerus USD 19.96M 4.29M Dec/2025
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 190M 136M Mar/2026
Dexcom USD 1.12B 200.5M Mar/2026
Illumina USD 1.42B 368M Dec/2025
Integra LifeSciences USD 236.81M 1.76M Mar/2026
Intuitive Surgical USD 7.98B 1.05B Mar/2026
IQVIA Holdings USD 1.95B 33M Mar/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Myriad Genetics USD 124.4M 25.2M Mar/2026
OraSure Technologies USD 176.96M 22.31M Mar/2026
Quidel USD 140.4M 29.4M Mar/2026
Repligen USD 582.65M 16.63M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
STAAR Surgical USD 153.15M 23M Dec/2025
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Trinity Biotech USD 1.34M 3.83M Sep/2025
Waters USD 462M 125.83M Mar/2026